Biophytis Unveils Phase 3 Sarcopenia Treatment Protocol

Biophytis SA, a Paris and Cambridge-based biotech firm, recently showcased its Phase 3 study protocol for testing the efficacy of RuvembriTM in sarcopenia treatment. This announcement was made at the International Conference on Frailty and Sarcopenia Research in Albuquerque, NM. The company's previous Phase 2 study, SARA-INT, illustrated promising results in enhancing physical performance in sarcopenic patients.

RuvembriTM's Phase 3 trial, named SARA-31, aims to enroll 932 participants in a randomized, double-blind, placebo-controlled study. This follows encouraging outcomes and insights from previous research, including SARA-INT, SPRINTT, and LIFE studies. Approval for the study has been secured in both Belgium and the United States. CEO Stanislas Veillet expressed optimism about the development and market potential of RuvembriTM for sarcopenia, highlighting the active search for pharmaceutical partnerships.